ArticleBJC reports2024

Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.

Takashi Oshima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.